CO2021003947A2 - Células productoras de insulina - Google Patents
Células productoras de insulinaInfo
- Publication number
- CO2021003947A2 CO2021003947A2 CONC2021/0003947A CO2021003947A CO2021003947A2 CO 2021003947 A2 CO2021003947 A2 CO 2021003947A2 CO 2021003947 A CO2021003947 A CO 2021003947A CO 2021003947 A2 CO2021003947 A2 CO 2021003947A2
- Authority
- CO
- Colombia
- Prior art keywords
- insulin
- cells
- producing cells
- positive
- proportion
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- 102000004877 Insulin Human genes 0.000 title abstract 4
- 108090001061 Insulin Proteins 0.000 title abstract 4
- 229940125396 insulin Drugs 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 abstract 2
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 abstract 2
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 abstract 2
- 210000003890 endocrine cell Anatomy 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018175465 | 2018-09-19 | ||
| PCT/JP2019/037725 WO2020059892A1 (ja) | 2018-09-19 | 2019-09-18 | インスリン産生細胞 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021003947A2 true CO2021003947A2 (es) | 2021-04-19 |
Family
ID=69887298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0003947A CO2021003947A2 (es) | 2018-09-19 | 2021-03-29 | Células productoras de insulina |
Country Status (14)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019169351A1 (en) | 2018-03-02 | 2019-09-06 | Semma Therapeutics, Inc. | Methods of enhancing stem cell differentiation into beta cells |
| CN112912490B (zh) * | 2018-08-03 | 2023-12-26 | 千纸鹤治疗公司 | 细胞制造方法 |
| EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
| JP7705448B2 (ja) | 2020-07-31 | 2025-07-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | 膵内分泌細胞の分化 |
| CN116391028A (zh) * | 2020-11-20 | 2023-07-04 | 千纸鹤治疗公司 | 促熟剂 |
| TW202246489A (zh) * | 2021-02-09 | 2022-12-01 | 日商千紙鶴治療公司 | 成熟化劑 |
| JP2024542041A (ja) | 2021-11-01 | 2024-11-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | 幹細胞由来の膵臓島分化 |
| IL315122A (en) * | 2022-04-25 | 2024-10-01 | Orizuru Therapeutics Inc | Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity |
| EP4596675A4 (en) | 2022-09-26 | 2026-03-11 | Univ Kyoto | PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS |
| EP4753734A1 (en) * | 2023-08-02 | 2026-06-10 | Joslin Diabetes Center, Inc. | Ribosomal remodeling in diabetes |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005096873A1 (de) | 2004-04-10 | 2005-10-20 | Henkel Kommanditgesellschaft Auf Aktien | Lockenwickler |
| EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| NZ571427A (en) * | 2006-03-02 | 2012-07-27 | Viacyte Inc | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| US7661738B2 (en) | 2006-11-28 | 2010-02-16 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
| MX348010B (es) | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
| JP2010528622A (ja) | 2007-05-30 | 2010-08-26 | ザ ジェネラル ホスピタル コーポレイション | 体細胞から多能性細胞を生成する方法 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009012428A2 (en) | 2007-07-18 | 2009-01-22 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| US9446168B2 (en) | 2010-06-07 | 2016-09-20 | Beta-O2 Technologies Ltd. | Multiple-layer immune barrier for donor cells |
| US9540630B2 (en) | 2008-09-17 | 2017-01-10 | Beta O2 Technologies Ltd. | Optimization of alginate encapsulation of islets for transplantation |
| JP5875597B2 (ja) * | 2010-12-08 | 2016-03-02 | ヴィアサイト,インコーポレイテッド | ヒト万能性幹細胞の成長を阻害する薬剤および方法 |
| US20120270890A1 (en) * | 2011-04-22 | 2012-10-25 | Cheng-Ho Chung | Methods of Pancreatic Beta Cell Regeneration |
| RU2705001C2 (ru) * | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
| IL321825A (en) * | 2013-02-06 | 2025-08-01 | Viacyte Inc | Cell compositions derived from dedifferentiated reprogrammed cells |
| WO2015002888A1 (en) * | 2013-07-01 | 2015-01-08 | Trustees Of Boston University | Dissolvable hydrogel compositions for wound management and methods of use |
| SG11201700874SA (en) | 2014-08-04 | 2017-03-30 | Takeda Pharmaceuticals Co | Method for proliferation of pancreatic progenitor cells |
| CN107250349A (zh) * | 2014-12-19 | 2017-10-13 | 詹森生物科技公司 | 多能干细胞的悬浮培养 |
| HK1254740A1 (zh) * | 2015-11-30 | 2019-07-26 | Kadimastem Ltd. | 分化和纯化胰腺内分泌细胞的方法 |
| MA45329A (fr) * | 2016-04-08 | 2019-02-13 | Univ California | Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines |
| JP6863805B2 (ja) | 2017-04-14 | 2021-04-21 | グローリー株式会社 | 各台装置及び各台装置制御方法 |
| AU2019261083B2 (en) * | 2018-04-23 | 2025-01-23 | Orizuru Therapeutics, Inc. | Growth inhibitor |
-
2019
- 2019-09-18 TW TW108133603A patent/TWI862513B/zh active
- 2019-09-18 EP EP19863748.0A patent/EP3854869A4/en active Pending
- 2019-09-18 CN CN201980061019.8A patent/CN112867787B/zh active Active
- 2019-09-18 US US17/277,406 patent/US20210353686A1/en active Pending
- 2019-09-18 BR BR112021004815-4A patent/BR112021004815A2/pt unknown
- 2019-09-18 CA CA3113608A patent/CA3113608A1/en active Pending
- 2019-09-18 SG SG11202102748WA patent/SG11202102748WA/en unknown
- 2019-09-18 WO PCT/JP2019/037725 patent/WO2020059892A1/ja not_active Ceased
- 2019-09-18 KR KR1020217006143A patent/KR102892433B1/ko active Active
- 2019-09-18 MX MX2021003147A patent/MX2021003147A/es unknown
- 2019-09-18 IL IL281531A patent/IL281531B2/en unknown
- 2019-09-18 JP JP2020549318A patent/JP7295576B2/ja active Active
- 2019-09-18 AU AU2019343003A patent/AU2019343003B2/en active Active
-
2021
- 2021-03-29 CO CONC2021/0003947A patent/CO2021003947A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019343003A1 (en) | 2021-05-13 |
| CN112867787B (zh) | 2024-11-22 |
| IL281531B1 (en) | 2024-11-01 |
| KR20210060446A (ko) | 2021-05-26 |
| BR112021004815A2 (pt) | 2021-06-01 |
| IL281531A (en) | 2021-05-31 |
| TW202026420A (zh) | 2020-07-16 |
| MX2021003147A (es) | 2021-05-14 |
| WO2020059892A1 (ja) | 2020-03-26 |
| IL281531B2 (en) | 2025-03-01 |
| SG11202102748WA (en) | 2021-04-29 |
| CA3113608A1 (en) | 2020-03-26 |
| EP3854869A4 (en) | 2022-09-07 |
| CN112867787A (zh) | 2021-05-28 |
| TWI862513B (zh) | 2024-11-21 |
| JP7295576B2 (ja) | 2023-06-21 |
| US20210353686A1 (en) | 2021-11-18 |
| JPWO2020059892A1 (ja) | 2021-08-30 |
| KR102892433B1 (ko) | 2025-11-27 |
| EP3854869A1 (en) | 2021-07-28 |
| AU2019343003B2 (en) | 2025-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081040A1 (es) | Diferenciacion de celulas madre embrionarias humanas | |
| CO2021001064A2 (es) | Método para la producción de las células t gamma delta | |
| AR082820A1 (es) | Diferenciacion de celulas madre embrionarias humanas | |
| CL2025001987A1 (es) | Método para producir una planta modificada. | |
| AR094348A1 (es) | Diferenciación de células madre embrionarias humanas a células pancreáticas endocrinas con el uso de reguladores hb9 | |
| BR112017004046A2 (pt) | processo de produção de butadieno e hidrogênio, a partir de etanol em duas etapas reacionais de baixo consumo em água e em energia | |
| AR077767A1 (es) | Diferenciacion de celulas madre embrionarias humanas | |
| AR094347A1 (es) | Cultivo de células madre embrionarias humanas en la interfase aire-líquido para la diferenciación en células endocrinas pancreáticas | |
| PE20181138A1 (es) | Metodo para producir l-aminoacidos | |
| AR090970A1 (es) | Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico | |
| PE20210105A1 (es) | Microorganismo del genero corynebacterium que produce l-aminoacidos y metodo para producir l-aminoacidos usando el mismo | |
| CL2016001883A1 (es) | Método para obtener cepas de levadura con producción de etanol baja, cepas de levadura obtenidas a partir de estas y su uso | |
| MX2019002154A (es) | Metodo de regulacion de caracteristica de planta. | |
| BR112015031233A2 (pt) | métodos de produção de derivados de ácidos graxos omega-hidroxilados | |
| CL2017000754A1 (es) | Proceso para producir una biomasa que contiene pufa que tiene alta estabilidad celular | |
| MX2021003147A (es) | Celulas productoras de insulina. | |
| CL2017001632A1 (es) | Manufactura de proteína. | |
| AR065634A1 (es) | Metodo para la produccion de acido citrico | |
| CO2021002704A2 (es) | Método de producción de precursores neuronales entéricos | |
| CL2022000470A1 (es) | Método para disminuir el contenido de glicoformas ricas en manosa de una proteína recombinante (divisional de la solicitud de patente no. 201601786) | |
| SG10201806655TA (en) | Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same | |
| PH12021550347A1 (en) | MICROORGANISM FOR PRODUCING L-AMINO ACID WITH ENHANCED ACTIVITY OF a-GLUCOSIDASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME | |
| PE20161484A1 (es) | Composiciones de siloxano y metodos para reducir los cov y el polvo de siloxano | |
| BR112016005456A2 (pt) | método para produzir um l-aminoácido por um método de fermentação, e, dna isolado | |
| CO2021008763A2 (es) | Enzima de desfosforilación del nuevo ácido psicosa-6-fosfórico, composición para producir psicosa que comprende la misma y método para preparar psicosa usando la misma |